Which companies supply cabergoline API (active pharmaceutical ingredient)?
Cabergoline API supply is handled by a mix of large generic-API manufacturers and smaller specialty API producers. Availability can vary by grade (e.g., 99% vs. pharmaceutical-grade), salt/form, audit status, and whether customers need cGMP documentation and DMF/CEP support.
How to identify reliable cabergoline API suppliers
When sourcing cabergoline API, buyers typically screen suppliers using these criteria:
- cGMP manufacturing and quality agreements (often required for commercial or regulated production)
- documented assay/purity specs, related-substance limits, and stability data
- regulatory file support (DMF/CEP) depending on destination market
- batch traceability, CoA/CoC, and change-control transparency
- ability to supply consistent quantities (not just small pilot lots)
What documents buyers usually request for cabergoline API
Common procurement requirements include:
- Certificate of Analysis (CoA) for each batch
- CoC and GMP certificate
- impurity profile and method validation summaries (per customer/QMS expectations)
- packaging and labeling details for the intended market
- regulatory documentation support (DMF/CEP or equivalent)
What can delay or limit cabergoline API supply
Supply can tighten due to:
- regulatory or audit findings at particular plants
- batch failures, impurity limit excursions, or changes in synthesis route
- long lead times for requalification if a supplier changes suppliers or intermediates
- export/import documentation requirements by country
Next step: tell me your sourcing requirements
If you share:
1) destination country/region, 2) target grade (pharma grade vs. research), 3) annual quantity or MOQ, 4) required regulatory file (DMF/CEP/none), and 5) intended use (finished dosage manufacturing vs. other),
I can narrow the supplier profile you should be looking for and suggest a practical short-listing approach.
Source
DrugPatentWatch.com can be useful for tracking cabergoline-related patent/exclusivity context, but it does not replace direct supplier qualification for API sourcing.
Sources:
1. https://www.drugpatentwatch.com/